HLB Life Science Co Ltd
KOSDAQ:067630
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
H
|
HLB Life Science Co Ltd
KOSDAQ:067630
|
523.9B KRW |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
120.4B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
72.4B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
71.3B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
53.6B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.7B AUD |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.8B USD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.9B CNY |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
62.7B CNY |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
66B HKD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
HLB Life Science Co Ltd
Glance View
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for HLB Life Science Co Ltd is 1.2%, which is above its 3-year median of -2.1%.
Over the last 3 years, HLB Life Science Co Ltd’s Gross Margin has increased from -6.7% to 1.2%. During this period, it reached a low of -6.7% on Sep 30, 2022 and a high of 1.2% on Sep 30, 2025.
